PFE 10-K Annual Report Dec. 31, 2021 | Alphaminr

Effective Date August 11, 2021

These terms and conditions govern your use of the website alphaminr.com and its related services.

These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.

Subscription

Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.

Fees

We will provide you with advance notice of any change in fees.

Usage

You represent that you are of legal age to form a binding contract. You are responsible for any activity associated with your account. The account can be logged in at only one computer at a time.
The Services are intended for your own individual use. You shall only use the Services in a manner that complies with all laws. You may not use any automated software, spider or system to scrape data from Alphaminr.

Limitation of Liability

Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.

TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.

If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.

PFIZER INC

10-Ks and 10-Qs

10-Q	Quarter ended March 31, 2024
10-K	Fiscal year ended Dec. 31, 2023
10-Q	Quarter ended Oct. 1, 2023
10-Q	Quarter ended July 2, 2023
10-Q	Quarter ended April 2, 2023
10-K	Fiscal year ended Dec. 31, 2022
10-Q	Quarter ended Oct. 2, 2022
10-Q	Quarter ended July 3, 2022
10-Q	Quarter ended April 3, 2022
10-K	Fiscal year ended Dec. 31, 2021
10-Q	Quarter ended Oct. 3, 2021
10-Q	Quarter ended July 4, 2021
10-Q	Quarter ended April 4, 2021
10-K	Fiscal year ended Dec. 31, 2020
10-Q	Quarter ended Sept. 27, 2020
10-Q	Quarter ended June 28, 2020
10-Q	Quarter ended March 29, 2020
10-K	Fiscal year ended Dec. 31, 2019
10-Q	Quarter ended Sept. 29, 2019
10-Q	Quarter ended June 30, 2019
10-Q	Quarter ended March 31, 2019
10-K	Fiscal year ended Dec. 31, 2018
10-Q	Quarter ended Sept. 30, 2018
10-Q	Quarter ended July 1, 2018
10-Q	Quarter ended April 1, 2018
10-K	Fiscal year ended Dec. 31, 2017
10-Q	Quarter ended Oct. 1, 2017
10-Q	Quarter ended July 2, 2017
10-Q	Quarter ended April 2, 2017
10-K	Fiscal year ended Dec. 31, 2016
10-Q	Quarter ended Oct. 2, 2016
10-Q	Quarter ended July 3, 2016
10-Q	Quarter ended April 3, 2016
10-K	Fiscal year ended Dec. 31, 2015
10-Q	Quarter ended Sept. 27, 2015
10-Q	Quarter ended June 28, 2015
10-Q	Quarter ended March 29, 2015
10-K	Fiscal year ended Dec. 31, 2014
10-Q	Quarter ended Sept. 28, 2014
10-Q	Quarter ended June 29, 2014
10-Q	Quarter ended March 30, 2014
10-K	Fiscal year ended Dec. 31, 2013
10-Q	Quarter ended Sept. 29, 2013
10-Q	Quarter ended June 30, 2013
10-Q	Quarter ended March 31, 2013
10-K	Fiscal year ended Dec. 31, 2012
10-Q	Quarter ended Sept. 30, 2012
10-Q	Quarter ended July 1, 2012
10-Q	Quarter ended April 1, 2012
10-K	Fiscal year ended Dec. 31, 2011
10-Q	Quarter ended Oct. 2, 2011
10-Q	Quarter ended July 3, 2011
10-Q	Quarter ended April 3, 2011
10-K	Fiscal year ended Dec. 31, 2010
10-Q	Quarter ended Oct. 3, 2010
10-Q	Quarter ended July 4, 2010
10-Q	Quarter ended April 4, 2010
10-K	Fiscal year ended Dec. 31, 2009

PROXIES

DEF 14A	Filed on March 14, 2024
DEF 14A	Filed on March 16, 2023
DEF 14A	Filed on March 17, 2022
DEF 14A	Filed on March 12, 2021
DEF 14A	Filed on March 13, 2020
DEF 14A	Filed on March 14, 2019
DEF 14A	Filed on March 15, 2018
DEF 14A	Filed on March 16, 2017
DEF 14A	Filed on March 15, 2016
DEF 14A	Filed on March 12, 2015
DEF 14A	Filed on March 13, 2014
DEF 14A	Filed on March 14, 2013
DEF 14A	Filed on March 15, 2012
DEF 14A	Filed on March 22, 2011
DEF 14A	Filed on March 16, 2010

TABLE OF CONTENTS

Part I Item 1. Business Item 1A. Risk Factors Covid-19 Pandemic Item 1A. Risk Factors Concentration Item 1A. Risk Factors Collaborations and Other Relationships with Third Parties Item 1A. Risk Factors Research and Development Item 1A. Risk Factors Item 1. Business Item 1A. Risk Factors Item 1. Business Patents and Other Intellectual Property Rights Item 1. Business Government Regulation and Price Constraints Item 2. Properties Item 3. Legal Proceedings Part II Item 5. Market For The Company S Common Equity, Related Stockholder Matters and Issuer Purchases Of Equity Securities Item 6. [reserved]Item 7. Management S Discussion and Analysis Of Financial Condition and Results Of Operations Item 1. Business Commercial Operations Note 16a1 Item 1A. Risk Factors Product Manufacturing, Sales and Marketing Risks Item 1A. Risk Factors Post-authorization/approval Data Note 7a, 7B Item 1A. Risk Factors Global Operations Item 7A. Quantitative and Qualitative Disclosures About Market Risk Item 8. Financial Statements and Supplementary Datareport Of Independent Registered Public Accounting Firm Item 8. Financial Statements and Supplementary Data Note 1. Basis Of Presentation and Significant Accounting Policies Note 2. Acquisitions, Divestitures, Equity-method Investments, Licensing Arrangements and Collaborative Arrangements Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-reduction/productivity Initiatives Note 4. Other (income)/deductions Net Note 5. Tax Matters Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests Note 7. Financial Instruments Note 8. Other Financial Information Note 9. Property, Plant and Equipment (pp&e)Note 10. Identifiable Intangible Assets and Goodwill Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans Note 12. Equity Note 13. Share-based Payments Note 14. Earnings Per Common Share Attributable To Pfizer Inc. Common Shareholders Note 15. Leases Note 16. Contingencies and Certain Commitments Note 17. Segment, Geographic and Other Revenue Information Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure Item 9A. Controls and Procedures Part III Item 10. Directors, Executive Officers and Corporate Governance Item 11. Executive Compensation Item 12. Security Ownership Of Certain Beneficial Owners and Management and Related Stockholder Matters Item 13. Certain Relationships and Related Transactions, and Director Independence Item 14. Principal Accounting Fees and Services Part IV Item 15. Exhibits, Financial Statement Schedules Item 8. Financial Statements and Supplementary Data Item 16. Form 10-k Summary

Exhibits

10.32 Letter to Frank A. DAmelio regarding replacement pension benefit dated August 22, 2007 is incorporated by reference from our Current Report on Form 8-K filed on August 22, 2007. 10.33 Pfizer Inc. Executive Severance Plan is incorporated by referenced from our Current Report on Form 8-K filed on February 20, 2009. 10.34 Amendment No. 1 to the Pfizer Inc. Executive Severance Plan is incorporated by reference from our 2018 Annual Report on Form 10-K. 10.35 Amendment No. 2 to the Pfizer Inc. Executive Severance Plan is incorporated by reference from our 2019 Annual Report on Form 10-K. 10.36 Amendment No. 3 to the Pfizer Inc. Executive Severance Plan is incorporated by reference from our 2020 Annual Report on Form 10-K. 10.37 Annual Retainer Unit Award Plan (for Non-Employee Directors) (frozen as of March 1, 2006) as amended, is incorporated by reference from our 2008 Annual Report on Form 10-K. 10.38 Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors, as amended, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended September 28, 2014. 10.39 Form of Special Award Letter Agreement is incorporated by reference from our Current Report on Form 8-K filed on October 28, 2009. 10.40 Offer Letter to G. Mikael Dolsten, dated April 6, 2009, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended April 3, 2011. 10.41 Form of Special Performance-Based Incentive Award Letter is incorporated by reference from our 2017 Annual Report onForm 10-K. 10.42 Form of Special Performance-Based Incentive Grant Letter is incorporated by reference from our 2017 Annual Report onForm 10-K. 10.44 Time Sharing Agreement, dated July 9, 2020, between Pfizer Inc. and Albert Bourla is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended June 28, 2020. *21 Subsidiaries of the Company. 22 Subsidiary Issuers of Guaranteed Securities is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended April 4, 2021. *23 Consent of Independent Registered Public Accounting Firm. *31.1 Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *31.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *32.1 Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *32.2 Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.

FUND	NUMBER OF SHARES	VALUE ($)	PUT OR CALL

DIRECTORS	AGE	BIO	OTHER DIRECTOR MEMBERSHIPS

Customers

Customer name	Ticker
Aflac Incorporated	AFL
Cigna Corporation	CI
CNO Financial Group, Inc.	CNO
CVS Health Corporation	CVS
DaVita Inc.	DVA
Humana Inc.	HUM
The Kroger Co.	KR
MetLife, Inc.	MET
Principal Financial Group, Inc.	PFG
Anthem, Inc.	ANTM
UnitedHealth Group Incorporated	UNH

Suppliers

Supplier name	Ticker
Air Products and Chemicals, Inc.	APD
Church & Dwight Co., Inc.	CHD
Illinois Tool Works Inc.	ITW
Waters Corporation	WAT
Jacobs Engineering Group Inc.	J
Thermo Fisher Scientific Inc.	TMO
Veeva Systems Inc.	VEEV
Corning Incorporated	GLW

Owner	Position	Direct Shares	Indirect Shares